97095 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof Translation products from oncogenes
METHOD FOR PRODUCING ONE OR SEVERAL SHARED CANCER EPITOPE(S) DERIVED FROM ALTERNATIVE TRANSLATIONAL CONTROL
#2Fully-human T cell receptor specific for the 369-377 epitope derived from the HER2/Neu (ERBB2) receptor protein
#3Compositions And Methods For Enhancing Adoptive T Cell Therapeutics
#4OLIGO-TRAP FUSION PROTEINS (OFPs) AND USES THEREOF
#5RNA ENGINEERED T CELLS FOR THE TREATMENT OF CANCER
#6ANTI-KRAS-G12D T CELL RECEPTORS
#7Lamp Constructs Comprising Cancer Antigens
#8NANOPARTICLE FORMULATIONS
#9TUMOR NEOANTIGENIC PEPTIDES
#10MODRNA-BASED CAS ENDONUCLEASE AND BASE EDITOR AND USES THEREOF
#11GENE MUTATIONS AND COPY NUMBER ALTERATIONS OF EGFR, KRAS AND MET
#12ANTI-MUTATED KRAS T CELL RECEPTORS
#13HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS
#14FUSION PROTEINS AND METHODS THEREOF
#15KIF5B-RET FUSION MOLECULES AND USES THEREOF
#16CHIMERIC CYTOKINE RECEPTORS
#17C-JUN ANTAGONIST PEPTIDES
#18Modified Cell Expansion and Uses Thereof
#19BCR-ABL VARIANTS
#20HER-1, HER-3 AND IGF-1R COMPOSITIONS AND USES THEREOF
#21COMPOSITIONS AND METHODS FOR INDUCING ESR1, PI3K, HER2, AND HER3 IMMUNE RESPONSES
#22UNIVERSAL STEM CELL AND USES THEREOF
#23METHODS AND COMPOSITIONS FOR TREATING CANCER
#24A SHORTENED P63-PROTEIN DOMAIN TO ENHANCE HUMAN CARDIAC REPROGRAMMING
#25FUSION PROTEINS COMPRISING SUPPRESSION OF TUMORIGENICITY 2 OR INTERLEUKIN-33, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
#26METHODS FOR GENERATING PRIMARY IMMUNE CELLS
#27METHODS OF DETECTING MLH1 METHYLATION
#28COMBINATION USE OF WT1 ANTIGEN PEPTIDE AND IMMUNOMODULATOR
#29FUSION PROTEINS AND METHODS THEREOF
#30Compositions and methods for enhancing adoptive T cell therapeutics
#31NOVEL TARGETS FOR ENHANCING ANTI-TUMOR IMMUNITY
#32FUSION PROTEINS AND METHODS THEREOF
#33ARENAVIRUSES AS VECTORS
#34ANTI-KRAS-G12D T CELL RECEPTORS
#35GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS DELIVERING CHEMOKINE AND TUMOR ASSOCIATED/SPECIFIC ANTIGEN
#36HLA-RESTRICTED EPITOPES ENCODED BY SOMATICALLY MUTATED GENES
#37COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICS
#38MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENIFYING AGENTS THAT MODULATE MYC
#39INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF
#40TREATMENT OF CANCER ASSOCIATED WITH VARIANT NOVEL OPEN READING FRAMES
#41Nucleic Acid Molecule Binding to YB-1 Protein
#42THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND USES THEREOF
#43RAS MUTANT EPITOPE PEPTIDE AND T CELL RECEPTOR RECOGNIZING RAS MUTANT
#44T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS
#45LISTERIA-BASED COMPOSITIONS COMPRISING A PEPTIDE MINIGENE EXPRESSION SYSTEM AND METHODS OF USE THEREOF
#46PROTEASE CLEAVABLE BISPECIFIC ANTIBODIES AND USES THEREOF
#47DESTABILIZED ARE 3'UTRs AS THERAPEUTICS FOR CANCER
#48HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
#49METHODS FOR CULTURING CELLS EXPRESSING C-JUN
#50T CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
#51Stabilized BCL9 peptides for treatment of aberrant Wnt signaling
#52KIF5B-RET fusion molecules and uses thereof
#53NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS
#54PROTEIN SECRETORY FACTOR WITH HIGH SECRETORY EFFICIENCY AND AN EXPRESSION VECTOR COMPRISING THE SAME
#55T cell-antigen coupler with various construct optimizations
#56RAS INHIBITORY PEPTIDES AND USES THEREOF
#57COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR EFFICIENCY
#58MOLECULES TARGETING RAS PROTEIN
#59METHODS OF TREATING CLEAR CELL RENAL CELL CARCINOMA (ccRCC) USING AXL DECOY RECEPTORS
#60DNA ANTIBODY CONSTRUCTS AND METHOD OF USING SAME
#61DISRUPTING GENOMIC COMPLEX ASSEMBLY IN FUSION GENES
#62MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENTIFYING AGENTS THAT MODULATE MYC
#63METHODS AND COMPOSITIONS FOR TREATING CANCER
#64p63 inactivation for the treatment of heart failure
#65Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/Neu (ERBB2) receptor protein
#66T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS
#67METHODS AND COMPOSITIONS FOR TREATING CANCER
#68BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE
#69GENE FRAGMENT OVEREXPRESSION SCREENING METHODOLOGIES, AND USES THEREOF
#70Modified BCL9 Mimetic Peptides
#71IDENTIFICATION OF RECURRENT MUTATED NEOPEPTIDES
#72Coordinating gene expression using RNA destabilizing elements
#73HLA class II-restricted t cell receptors against mutated RAS
#74TARGETING DEREGULATED WNT SIGNALING IN CANCER USING STABILIZED ALPHA-HELICES OF BCL-9
#75BCR-ABL variants
#76Methods and Compositions for Treating Melanoma
#77COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING HER2 EXON 21 INSERTIONS
#78RNA ENGINEERED T CELLS FOR THE TREATMENT OF CANCER
#79CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS
#80ANTI-HER2 BISPECIFIC ANTIBODY AND APPLICATION THEREOF
#81Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#82TETRAMERIC PROTEIN SCAFFOLDS AS NANO-CARRIERS OF THERAPEUTIC PEPTIDES FOR TREATING CANCER AND OTHER DISEASES
#83Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#84Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#85NANOPARTICLE FORMULATIONS
#86Anti-KRAS-G12D T cell receptors
#87SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS
#88Anti-mutated KRAS T cell receptors
#89Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#90Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#91CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF
#92Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#93METHOD AND KIT FOR TREATING A NEURODEGENERATIVE DISEASE
#94CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF
#95COMPOSITIONS AND METHODS UTILIZING GENETICALLY-MODIFIED ANIMALS AND CELLS
#96Gene mutations and copy number alterations of EGFR, KRAS and MET
#97Coordinating gene expression using RNA destabilizing elements
#98PROTEASE CLEAVABLE BISPECIFIC ANTIBODIES AND USES THEREOF
#99QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR FOR STABLE GENETIC MODIFICATION OF CELLULAR IMMUNOTHERAPIES
#100SNAP-25 REPORTER CONSTRUCTS AND METHODS OF USING THE SAME
#101T cell-antigen coupler with various construct optimizations
#102Anti-KRAS-G12D T cell receptors
#103Stabilized BCL9 peptides for treatment of aberrant WNT signaling
#104Coordinating Gene Expression Using RNA Destabilizing Elements
#105Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#106Methods of detecting MLH1 methylation
#107HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
#108Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof
#109Interleukin-2 fusion proteins and uses thereof
#110ENHANCED RECONSTITUTION AND AUTORECONSTITUTION OF THE HEMATOPOIETIC COMPARTMENT
#111Examination method for prediction of effect of treatment of cancer based on detection of cancer/testis antibodies
#112Fusions and method for detecting same
#113Peptide for treating cancer
#114Modified cell expansion and uses thereof
#115Translocation and mutant ROS kinase in human non-small cell lung carcinoma
#116Targeting deregulated Wnt signaling in cancer using stabilized alpha-helices of BCL-9
#117HER-1, HER-3 AND IGF-1R COMPOSITIONS AND USES THEREOF
#118BCR-ABL variants
#119CIP2A variant and uses thereof
#120METHOD FOR ACTIVATING HELPER T CELL
#121Tumor-selective CTLA-4 antagonists
#122Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#123CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS
#124Fusion proteins and methods thereof
#125Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#126T cell-antigen coupler with various construct optimizations
#127PROTEIN SECRETORY FACTOR WITH HIGH SECRETORY EFFICIENCY AND AN EXPRESSION VECTOR COMPRISING THE SAME
#128Anti-KRAS-T cell receptors
#129ANTICANCER PEPTIDES
#130Ras inhibitory peptides and uses thereof
#131Fully-human t-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein
#132Nanoparticle formulations
#133Compositions and methods for modulating immune cells
#134CHIMERIC ANTIGEN RECEPTOR FOR HER2/NEU AND T-CELLS EXPRESSING SAME
#135Fusion proteins and methods thereof
#136METHODS OF PRODUCING HUMAN CANCER CELL MODELS AND METHODS OF USE
#137METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
#138Antibodies and processes for preparing the same
#139T cell receptors recognizing HLA-CW8 restricted mutated KRAS
#140METHOD FOR DIRECT REPROGRAMMING OF URINE CELLS INTO KERATINOCYTE STEM CELLS AND METHOD FOR PREPARING COMPOSITION FOR PROMOTING SKIN REGENERATION USING REPROGRAMMED KERATINOCYTE STEM CELLS
#141HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
#142Anti-tumor properties of Dickkopf 3b
#143Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#144Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
#145Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
#146RNA engineered T cells for the treatment of cancer
#147IMPROVED LAMP CONSTRUCTS COMPRISING CANCER ANTIGENS
#148TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMA
#149Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
#150Fusion proteins and methods thereof
#151Fusion protein comprising bacteriophage λ GpD fused to a GP2 antigen derived from HER-2/neu
#152Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
#153Methods and compositions for the treatment of cancer
#154Coordinating gene expression using RNA destabilizing elements
#155FUSION PROTEIN AND APPLICATIONS THEREOF
#156Coordinating gene expression using RNA destabilizing elements
#157Use of peptides that block metadherin-SND1 interaction as treatment for cancer
#158Modified cell expansion and uses thereof
#159CRYPTIC POLYPEPTIDES AND USES THEREOF
#160Methods and compositions for treating melanoma
#161Gene mutations and copy number alterations of EGFR, KRAS and MET
#162Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
#163RhoC-Based Immunotherapy
#164Coordinating gene expression using RNA destabilizing elements
#165Therapeutic multi-targeting constructs and uses thereof
#166Methods for generating universal and custom MHC/HLA-compatible hematopoietic progenitor cells
#167HER-1, HER-3 and IGF-1R compositions and uses thereof
#168Methods of detecting MLH1 methylation
#169Anti-KRAS-G12D T cell receptors
#170Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#171MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571
#172Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
#173Ras binding peptides and methods of use
#174NOVEL CANCER ANTIGEN EEF2
#175Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#176HLA class II-restricted T cell receptors against mutated RAS
#177Brachyury protein, non-poxvirus non-yeast vectors encoding Brachyury protein, and their use
#178Fusions and method for detecting same
#179Conditionally immortalized long-term stem cells and methods of making and using such cells
#180Stabilized BCL9 peptides for treatment of aberrant WNT signaling
#181Immortalized stem cells and method for producing same
#182Method to risk-stratify patients with cancer based on the comorbidities, and related differential gene expression information
#183Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof
#184Nucleic acids encoding HLA-A24 agonist epitopes of MUC1-C oncoprotein
#185ANTI-TNF INDUCED APOPTOSIS (ATIA) DIAGNOSTIC MARKERS AND THERAPIES
#186Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#187Methods and compositions for treating cancer
#188Cyclic peptide binder against oncogenic K-Ras
#189Compositions and methods for improving viral vector efficiency
#190POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS
#191POLYPEPTIDES THAT BIND ACTIVATED RAS PROTEINS
#192NOVEL KIF5B-RET FUSION MOLECULES AND USES THEREOF
#193ERG targeted therapy
#194COMPOSITIONS AND METHODS FOR CREATING PANCREATIC CANCER ANIMAL MODEL
#195T cells modified to overexpress c-Myb
#196Methods for Optimizing CATS Immunotherapeutics into Humanized Derivatives with Reduced Autoreactivity, Reduced Toxicity and Enhanced Long-Term Efficacy
#197Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#198METHODS FOR IN VITRO PRODUCTION OF PLATELETS AND COMPOSITIONS AND USES THEREOF
#199Cell-penetrating ATF5 polypeptides and uses thereof
#200CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF
#201Tumor-selective CTLA-4 antagonists
#202Modified yeast-brachyury immunotherapeutic compositions
#203Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
#204Methods and compositions related to KRAS inhibitors
#205Cryptic polypeptides and uses thereof
#206Oral cancer vaccine
#207CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF
#208ANTI-5T4 ANTIBODIES AND USES THEREOF
#209Nanoparticle formulations
#210Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
#211Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
#212Compositions and methods for modulating an immune response
#213L-MYC Expression Maintains Self Renewal and Prolongs Multipotency of Primary Human Neural Stem Cells
#214METHODS AND COMPOSITIONS RELATING TO AN EMBRYONIC STEM CELL-BASED TUMOR MODEL
#215p63 inactivation for the treatment of heart failure
#216NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS
#217FUSION PROTEINS AND METHODS THEREOF
#218Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein
#219Peptide mixture
#220BCR-ABL variants
#221CELL FOR USE IN IMMUNOTHERAPY WHICH CONTAINS MODIFIED NUCLEIC ACID CONSTRUCT ENCODING WILMS TUMOR GENE PRODUCT OR FRAGMENT THEREOF, METHOD FOR PRODUCING SAID CELL, AND SAID NUCLEIC ACID CONSTRUCT
#222METHODS OF TREATING UROTHELIAL CARCINOMA
#223Substrates for FLT3 kinase and uses thereof
#224Peptide mixture
#225Anti-mutated KRAS T cell receptors
#226HER2DELTA16 peptides
#227Tumor antigen peptide
#228Cancer vaccine compositions and methods of use thereof
#229DNA antibody constructs and method of using same
#230Ras inhibitory peptides and uses thereof
#231ADENOCARCINOMA ANTIGENIC DETERMINANTS AND METHODS
#232Peptide mixture
#233Use of peptides that block metadherin-SND1 interaction as treatment for cancer
#234Peptide inhibitors of BCR-ABL oligomerization
#235METHOD FOR MEASURING ANTI-WT1 ANTIBODY
#236Methods and materials for treating cancer
#237Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent
#238Antibodies and processes for preparing the same
#239Protein secretory factor with high secretory efficiency and an expression vector comprising the same
#240Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#241Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#242Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#243Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#244Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
#245Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#246Method for treating cancer with an activated T lymphocyte that selectively recognizes a cancer cell consisting of specific peptide
#247Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#248Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#249Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#250Activity-dependent expression of nucleic acids
#251Selective inhibitors of c-Fos and their antiproliferative properties
#252Chimeric nucleic acid molecules with non-AUG translation initiation sequences and uses thereof
#253KIF5B-RET fusion molecules and uses thereof
#254Chimeric nucleic acid molecules with non-AUG translation initiation sequences and uses thereof
#255COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS
#256Expansion of adult stem cells in vitro
#257Chimeric nucleic acid molecules with non-AUG translation initiation sequences and uses thereof
#258TARGETING P53 AND ITS DNA-BINDING DOMAIN
#259Peptide mixture
#260Anti-tumor properties of Dickkopf 3b
#261Recurrent gene fusions in prostate cancer
#262MAFB MUTANTS AND USES THEREOF
#263Cyclic peptide binder against oncogenic K-Ras
#264HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
#265Inhibitor Peptides of ERK-type MAP kinase
#266Peptide compositions having 4 linked CTL epitopes and uses thereof
#267Interleukin-2 fusion proteins and uses thereof
#268Translocation and mutant ROS kinase in human non-small cell lung carcinoma
#269METHODS AND COMPOSITIONS FOR TREATMENT OF RETINOID-RESPONSIVE CONDITIONS
#270Anti-5T4 antibodies and uses thereof
#271Reconstituted Histone Methyltransferase Complex and Methods of Identifying Modulators Thereof
#272Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
#273Methods and compositions for the treatment of cancer
#274Interference peptides and use thereof
#275CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS
#276METHODS AND PHARMACEUTICALS COMPOSITIONS FOR TREATING BREAST CANCERS
#277Peptide having 5 linked CTL epitopes
#278Insulin like peptides
#279HER-1, HER-3 and IGF-1R compositions and uses thereof
#280Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins
#281Cancer antigen EEF2
#282Autophagy-inducing peptide analogs
#283COMPOSITIONS EMPLOYING ALTERNATIVE READING FRAME POLYPEPTIDES FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASE
#284Method of protein extraction from cells
#285Antibodies and processes for preparing the same
#286Conditionally immortalized long-term stem cells and methods of making and using such cells
#287Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
#288FUSION PROTEINS AND METHODS THEREOF
#289Albumin fusion proteins
#290Beclin 1 phosphorylation
#291AXL TYROSINE KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME
#292FUSION GENE OF CEP55 GENE AND RET GENE
#293Anti-tumor properties of Dickkopf 3b
#294Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
#295Process for producing poxviruses and poxvirus compositions
#296Nitration shielding peptides and methods of use thereof
#297Methods for identifying modulators of Ras using nonlinear techniques
#298Methods of treating urothelial carcinoma
#299Translocation and mutant ROS kinase in human non-small cell lung carcinoma
#300Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics